Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance

Lipids are essential constituents for malignant tumors, as they are absolutely required for tumor growth and dissemination. Provided by the tumor microenvironment (TME) or by cancer cells themselves through activation of de novo synthesis pathways, they orchestrate a large variety of pro-tumorigenic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogenesis (New York, NY) Jg. 11; H. 1; S. 46 - 15
Hauptverfasser: Vasseur, Sophie, Guillaumond, Fabienne
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 09.08.2022
Nature Publishing Group
Nature Publishing Group: Open Access Journals - Option C
Schlagworte:
13
38
631/67/2327
631/67/327
64
64/110
96
Adipocytes
Antibodies
Apoptosis
Cancer
Cell activation
Cell Biology
Cholesterol
Fatty acids
Fibroblasts
Glycerol
Human Genetics
Immunotherapy
Internal Medicine
Life Sciences
Lipids
Medicine
Medicine & Public Health
Metabolism
Metabolites
Metastases
Metastasis
Oncology
Oxidation
Review
Review Article
Treatment resistance
Tumor microenvironment
Tumors
Cancer metabolism
Cancer microenvironment
ISSN:2157-9024, 2157-9024
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lipids are essential constituents for malignant tumors, as they are absolutely required for tumor growth and dissemination. Provided by the tumor microenvironment (TME) or by cancer cells themselves through activation of de novo synthesis pathways, they orchestrate a large variety of pro-tumorigenic functions. Importantly, TME cells, especially immune cells, cancer-associated fibroblasts (CAFs) and cancer-associated adipocytes (CAAs), are also prone to changes in their lipid content, which hinder or promote tumor aggressiveness. In this review, we address the significant findings for lipid contribution in tumor progression towards a metastatic disease and in the poor response to therapeutic treatments. We also highlight the benefits of targeting lipid pathways in preclinical models to slow down metastasis development and overcome chemo-and immunotherapy resistance.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2157-9024
2157-9024
DOI:10.1038/s41389-022-00420-8